India’s Diagnostic, Pathology Industry Seen Making Consolidation Moves
This article was originally published in PharmAsia News
India's diagnostics and pathology industry is expected to begin a consolidation move as it continues growing at a rate of 10 percent to 12 percent a year. The head of an investment firm said several regional players are attempting to become the nation's first national player, but the route to get there is time-consuming and expensive. That, he said, leaves the firms with little choice but to merger with companies in similar situations. A consultant said diagnostics and pathology laboratories need to reduce their costs and could do that only by consolidating as they attempt to expand business. (Click here for more
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.